
## excelra

# Structuring Investigator's Brochures

A US based large pharma company approached Excelra to digitize and create a structured data model for their Investigator's Brochures.








#### **Results**

- All the IBs were screened, and a total of 358 variables were captured.
- These variables were then structured into 9 different sections.
- A data model was created from this and delivered post client's approval.


### The challenge

- Our client was a large pharma based out in the US and working on multiple therapeutic areas.
- Their data was unstructured Investigator's Brochures containing Preclinical data from animal models.
- Amongst these were the 65 IBs containing Pharmacokinetic and toxicity data that needed to be structured in a prescribed format.



#### Our approach

- We discussed the details of the project with the client and gathered the necessary information about the reports to be curated.
- The IBs were then manually curated and multiple variables were captured from the reports as discussed in the scope.
- These variables were then siloed into 9 different sections. A total of 358 variables were captured and put up into respective sections.
- A structured model was created from these sections and delivered to the client once approved by them.



### Assessment of exposure and relating exposure to safety and eficacy

#### Concentration vs time **Exposure vs exposure** 80 Mean plasma concentration (ng/mL) 100000 70 ◆ Irinotecan IndividualMeanMedian ■ Floxuridine 80000 (mg/mr) 60 ▲ 5-FU ■ SN-38 50 60000 40 40000 Floxuridine 30 $R^2 = 0.964$ 20000 20 10 0 12 24 36 48 60 72 84 96 0 Time (h) 0 60 80 Floxuridine dose (mg/m²) **Compare interventions Exposure vs toxicity Exposure vs efficacy** AUC<sub>24</sub> $R_s = 0.76$ 100 200000 **Leduction** 1.5 ▲ d-p-OCH3 150000 100000 <u>Σ</u> 10 를 <sub>1.0</sub> 9 <sub>0.5</sub> 50000 0.0 Mean I 0 10 100 0 20 40 60 80 100 120 140 160 180 200 No Yes

Dizziness

 $Lung_C_{max}$ 

#### The results

• A well-structured model with all the data consolidated into it was delivered to the client for further analysis.

#### Conclusion

- The Investigator's Brochure is an extensive document of the clinical and non-clinical data of the assets in the portfolio and is of critical importance.
- This information is usually captured by different people who are part of the trials and is unstructured making it difficult for any analysis.
- Excelra contributed by structuring all the available data in a unified fashion which clients can use for further analysis using our Preclinical Tox Report Digitization (PTRD) curation services.
- The details from the IBs were refined and structured by creating multiple data sections and the variables were annotated and mapped to the accurate section.
- A final data model was created using this and delivered to the client for their further analysis.